Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$207K Buy
+1,131
New +$208K 0.03% 227
2024
Q3
Sell
-938
Closed -$217K 228
2024
Q2
$217K Buy
+938
New +$204K 0.05% 197
2023
Q3
Sell
-708
Closed -$202K 181
2023
Q2
$202K Buy
+708
New +$211K 0.04% 186
2022
Q4
$205K Sell
741
-22
-3% -$6.21K 0.05% 175
2022
Q3
$204K Buy
+763
New +$162K 0.05% 167
2022
Q1
Sell
-958
Closed -$230K 187
2021
Q4
$230K Sell
958
-429
-31% -$110K 0.05% 181
2021
Q3
$393K Buy
1,387
+10
+0.7% +$3.28K 0.08% 154
2021
Q2
$477K Buy
1,377
+50
+4% +$15.1K 0.1% 134
2021
Q1
$371K Buy
+1,327
New +$358K 0.08% 147
2020
Q3
$348K Sell
1,226
-20
-2% -$5.58K 0.1% 139
2020
Q2
$333K Sell
1,246
-26
-2% -$7.82K 0.1% 138
2020
Q1
$402K Sell
1,272
-44
-3% -$13.4K 0.15% 117
2019
Q4
$390K Sell
1,316
-92
-7% -$25.5K 0.12% 134
2019
Q3
$328K Buy
1,408
+163
+13% +$38K 0.11% 139
2019
Q2
$291K Buy
1,245
+138
+12% +$31.9K 0.1% 151
2019
Q1
$262K Buy
1,107
+39
+4% +$12.3K 0.09% 150
2018
Q4
$321K Sell
1,068
-26
-2% -$8.3K 0.12% 133
2018
Q3
$387K Buy
1,094
+20
+2% +$6.89K 0.13% 122
2018
Q2
$312K Buy
1,074
+63
+6% +$17.7K 0.11% 130
2018
Q1
$277K Buy
1,011
+133
+15% +$41.3K 0.1% 137
2017
Q4
$280K Buy
878
+73
+9% +$23.4K 0.1% 134
2017
Q3
$252K Buy
805
+37
+5% +$11K 0.09% 127
2017
Q2
$208K Buy
+768
New +$203K 0.08% 135

Other funds holding BIIB

Probity Advisors's BIIB Position: Q1 2026 in Review

Probity Advisors opened a new position in Biogen (BIIB) in Q1 2026: 1,131 shares worth $207K. The stake represents 0.03% of the portfolio and ranks #227 among its holdings. This is a return to the name: Probity Advisors previously reported a position in BIIB as recently as Q2 2024.

Probity Advisors first reported a position in BIIB in Q2 2017 and has held it in 23 quarters since. The position peaked at $477K in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Probity Advisors held 1,131 shares of Biogen worth $207K as of Q1 2026.
  • Biogen was a new Probity Advisors position in Q1 2026.
  • Biogen made up 0.03% of Probity Advisors's portfolio in Q1 2026, its #227 holding.
  • Probity Advisors first reported a position in Biogen in Q2 2017 and has held it in 23 quarters since.
  • Probity Advisors's Biogen position peaked at $477K in Q2 2021.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Probity Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.